July 2026 in “Journal of the American Academy of Dermatology”
January 2025 in “International journal of research and scientific innovation” This critique of a 2019 study highlights the potential of a liposomal hydrogel for delivering Minoxidil and Tretinoin to treat androgenetic alopecia, but underscores the need for in vivo trials and further stability and interaction analysis to validate its promise.
February 2024 in “Current Drug Delivery” In this study, researchers developed an emulgel formulation containing minoxidil for hair growth, using chitosan and fucoidan as gelling agents, achieving controlled drug release with 99.7% released by the 12th hour.
June 2026 in “International Journal of Drug Delivery Technology” This study highlights the potential of polymeric micelles in enhancing the targeted delivery and efficacy of treatments for androgenetic alopecia, by offering improved retention on the scalp, extended release, and reduced systemic side effects compared to conventional therapies like minoxidil and finasteride.
November 2024 in “ACS Materials Letters” This study developed a nitric oxide delivery system using PVA films and HA liposomes, which enhanced hair follicle vitality and repaired blood vessels in androgenic alopecia by promoting angiogenesis and reducing inflammation through the HIF-1 signaling pathway.